Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2018
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Arteriovenous malformations
- Focus Therapeutic Use
- Acronyms MAV-RAPA
- 09 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2020.
- 09 Aug 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2020.
- 02 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.